North America Neoantigens Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Treatment (Combination Therapy and Mono Therapy) and Therapeutic Specialty (Gastrointestinal Cancer, Lung Cancer, Solid Tumor, Urinary Systems Cancers, Melanoma, Head and Neck Cancer, and Others)

Code: TIPRE00025573 | Pages: 68 | Industry: Pharmaceuticals | Date: Nov 2021
Covid

Market Introduction

North America consists of three countries, namely the US, Canada, Mexico. The US is the largest market for neoantigens, followed by Canada and Mexico. The growing numbers of clinical trials, growing advancements for immunotherapies to treat cancer, and growing support from the governments in the respective countries are driving the growth of market. Moreover, the significantly rising incidences of cancers in all the countries in the North American region are likely to serve growth opportunities for the market during the forecast period. The US is estimated to be the largest market for the neoantigens in the North American region. The growing numbers of clinical trials, increasing investments for research and development of neoantigens, rising collaborations between the companies are driving the growth of the market in the country. In addition, the significantly increased incidences of cancers are equally contributing to the growth of the market. The growing incidences of cancers have become a burden on the healthcare systems. Therefore, public and private players have initiated several programs to address the increasing incidences of cancers. To implement preventive and control measures, government and private agencies are supporting clinical trials for neoantigens. For instance, as per the publication of the FDA in November 2020, the FDA’s oncology staff receives support from the OCE Scientific Collaborative to participate in regulatory science research, such as internal research projects and collaborations with external experts. The OCE has identified FDA Broad Agency Announcement as a research funding method supporting nine areas of scientific interest, including cell/gene and personalized neo-antigen-based therapies for cancer. Therefore, OCE aims to facilitate regulatory works such as development, optimization and standardize the algorithm for neoantigens identification. Also, it aims to create approaches to evaluate the safety and efficacy of neoantigens. Further, it also aims to implement innovative clinical trials for neoantigen-based therapies. Moreover, various updated clinical trials are being published in the country. For instance, at American Association for Cancer Research Annual Meeting 2020, updates related to iNeST, developed by Roche’s Genentech and BioNTech for the combination therapy, were released. iNeST was combined with ICI and administered to patients living with solid metastatic tumors. Such developments for antigens are expected to leverage the growth of the market in the coming near future.

 

The impacts of COVID-19 pandemic are being felt across several markets in North America. Although the healthcare sector had witnessed SARS, H1N1, and other outbreaks in the last few years, the severity of the COVID-19 has made the situation more complicated due to its mode of transmission. North America has been witnessing growing number of COVID-19 cases since its outbreak. For instance, according to WHO, from January 3, 2020 to May 5, 2021, there have been 32,123,136 confirmed cases of COVID-19 with 572,190 deaths. The cases are also increasing in Mexico and Canada. In Mexico, the cases have reached to 2,355,985 with 218,007 deaths. Similarly, in Canada, there are about 1,257,328 COVID-19 cases, with 24,450 deaths reported so far. In the US, many doctors, hospitals, and other healthcare facilities are delaying or canceling the cancer procedures, surgeries, and sometimes screenings or other treatments, if it is not considered urgent, emergency, or life-threatening condition. Due to weak immune system, cancer patients are requested to follow social distancing norms as they are more prone to get infected with virus that causes COVID-19. More research is being conducted on COVID-19 vaccines other than any other disease vaccine. For instance, a research study on “Cancer therapy tool informs COVID-19 vaccines” was published on April 2020 in Icahn School of Medicine at Mount Sinai, New York, NY, USA. In this study, a computational tool was designed to predict candidate neoantigens for cancer vaccines, which helps in the formation of T-cell vaccines against SARS-CoV-2. Pharmaceutical companies are halting ongoing studies and delaying the launch of new trials. Therefore, owing to these points, the pandemic is likely to affect cancer vaccine market.


Get more information on this report :



Market Overview and Dynamics

The neoantigens market in North America is expected to grow from US$ 127,564.64 thousand in 2023 to US$ 501,233.14 thousand by 2028; it is estimated to grow at a CAGR of 31.5% from 2023 to 2028. Increasing prevalence of cancer; cancer has emerged as a leading cause death worldwide. According to the World Health Organization (WHO), cancer was the first leading cause of death in the people of age below 70 years in 183 countries and fourth leading cause of death in 123 countries worldwide in 2019. In addition, according to data published by the WHO in March 2021, ~10 million deaths occurred in 2020 due to different cancer type. The increasing prevalence of cancer has created burden on the healthcare systems across the world. According to International Agency for Research on Cancer (IARC), the global burden of new cancer cases is estimated to reach ~ 27.5 million by 2040, and the disease likely to be a cause of ~163 million deaths by that year. Factors such as lifestyle changes, smoking, reduced physical activities, and uncertain health and climatic conditions are likely to lead to even greater burden of cancer in the world in the coming years. Therefore, it is essential to control and prevent the increasing number of cancers worldwide This is bolstering the growth of the neoantigens market.

Key Market Segments

Based on treatment, the market is segmented into combination therapy, and mono therapy. In 2023, the combination therapy segment is estimated to have the largest share of the market. Based on therapeutic specialty, the market is segmented into gastrointestinal cancer, lung cancer, solid tumor, urinary systems cancers, melanoma, head and neck cancer, and others. In 2023, the gastrointestinal cancer segment is estimated to hold the largest share of the market.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the neoantigens market in North America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Advaxis, Inc., Gradalis, Inc., Gritstone Oncology, Medigene AG, Moderna, Inc., and Ziopharm Oncology, Inc among others.

Reasons to buy report

  • To understand the North America neoantigens market landscape and identify market segments that are most likely to guarantee a strong return
  • Stay ahead of the race by comprehending the ever-changing competitive landscape for North America neoantigens market
  • Efficiently plan M&A and partnership deals in North America neoantigens market by identifying market segments with the most promising probable sales
  • Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form North America neoantigens Market
  • Obtain market revenue forecast for market by various segments from 2021-2028 in North America region.

 

 

 

NORTH AMERICA NEOANTIGENS MARKET SEGMENTATION

 

 

By Treatment

  • Combination Therapy
  • Mono Therapy

 

By Therapeutic Specialty

  • Gastrointestinal Cancer
  • Lung Cancer
  • Solid Tumors
  • Urinary System Cancers
  • Melanoma
  • Head and Neck Cancer
  • Others

By Country

  • US
  • Canada
  • Mexico

Company Profiles

  • Advaxis, Inc.
  • Gradalis, Inc.
  • Gritstone Oncology
  • Medigene AG
  • Moderna, Inc.
  • Ziopharm Oncology, Inc
 

1.           Introduction

1.1          Scope of the Study

1.2          The Insight Partners Research Report Guidance

1.3          Market Segmentation

1.3.1          North America Neoantigens Market – By Treatment

1.3.2          North America Neoantigens Market – By Therapeutic Specialty

1.3.3          North America Neoantigens Market– By Country

2.           North America Neoantigens Market – Key Takeaways

3.           Research Methodology

3.1          Coverage

3.2          Secondary Research

3.3          Primary Research

4.           North America Neoantigens Market– Market Landscape

4.1          Overview

4.2          PEST Analysis

4.2.1          North America PEST Analysis

4.3          Expert Opinion

5.           North America Neoantigens Market – Key Market Dynamics

5.1          Market Drivers

5.1.1          Developments in Neoantigen Vaccines Against Cancer

5.1.2          Increasing Prevalence of Cancer

5.2          Market Restraints

5.2.1          Possible Side Effects Associated with Neoantigen Vaccines

5.3          Market Opportunities

5.3.1          Application of Next-generation Sequencing for Neoantigen Identification

5.4          Future Trends

5.4.1          Use of AI in Neoantigen Vaccine Development

5.5          Impact Analysis

6.           Neoantigens Market – North America Analysis

6.1          North America Neoantigens Market Revenue Forecast and Analysis

7.           North America Neoantigens Market Analysis – By Treatment

7.1          Overview

7.2          North America Neoantigens Market Revenue Share, by Treatment (2023 and 2028)

7.3          Combination Therapy

7.3.1          Overview

7.3.2          Combination Therapy: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

7.4          Mono Therapy

7.4.1          Overview

7.4.2          Mono Therapy: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.           North America Neoantigens Market Analysis – By Therapeutic Specialty

8.1          Overview

8.2          North America Neoantigens Market Revenue Share, by Therapeutic Specialty (2023 and 2028)

8.3          Gastrointestinal Cancer

8.3.1          Overview

8.3.2          Gastrointestinal Cancer: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.4          Lung Cancer

8.4.1          Overview

8.4.2          Lung Cancer: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.5          Solid Tumors

8.5.1          Overview

8.5.2          Solid Tumors: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.6          Urinary System Cancers

8.6.1          Overview

8.6.2          Urinary System Cancers: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.7          Melanoma

8.7.1          Overview

8.7.2          Melanoma: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.8          Head and Neck Cancers

8.8.1          Overview

8.8.2          Head and Neck Cancers: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.9          Others

8.9.1          Overview

8.9.2          Others: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

9.           North America Neoantigens Market – Country Analysis

9.1          North America: Neoantigens Market Revenue and Forecast to 2028

9.1.1          Overview

9.1.2          North America: Neoantigens Market, by Country, 2023 & 2028 (%)

9.1.3          US: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.3.1             US: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.3.2             US: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.1.3.3             US: Neoantigens Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)

9.1.4          Canada: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.4.1             Canada: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.4.2             Canada: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.1.4.3             Canada: Neoantigens Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)

9.1.5          Mexico: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.5.1             Mexico: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.5.2             Mexico: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.1.5.3             Mexico: Neoantigens Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)

10.        Impact Of COVID-19 Pandemic on North America Neoantigens Market

10.1        North America: Impact Assessment of COVID-19 Pandemic

11.        North America Neoantigens Market–Industry Landscape

12.        Company Profiles

12.1        Advaxis, Inc.

12.1.1        Key Facts

12.1.2        Business Description

12.1.3        Products and Services

12.1.4        Financial Overview

12.1.5        SWOT Analysis

12.1.6        Key Developments

12.2        Gradalis, Inc.

12.2.1        Key Facts

12.2.2        Business Description

12.2.3        Products and Services

12.2.4        Financial Overview

12.2.5        SWOT Analysis

12.2.6        Key Developments

12.3        Gritstone Oncology

12.3.1        Key Facts

12.3.2        Business Description

12.3.3        Products and Services

12.3.4        Financial Overview

12.3.5        SWOT Analysis

12.3.6        Key Developments

12.4        Medigene AG

12.4.1        Key Facts

12.4.2        Business Description

12.4.3        Products and Services

12.4.4        Financial Overview

12.4.5        SWOT Analysis

12.4.6        Key Developments

12.5        Ziopharm Oncology, Inc.

12.5.1        Key Facts

12.5.2        Business Description

12.5.3        Products and Services

12.5.4        Financial Overview

12.5.5        SWOT Analysis

12.5.6        Key Developments

12.6        Moderna, Inc.

12.6.1        Key Facts

12.6.2        Business Description

12.6.3        Products and Services

12.6.4        Financial Overview

12.6.5        SWOT Analysis

12.6.6        Key Developments

13.        Appendix

13.1        About the Insight Partners

13.2        Glossary of Terms

LIST OF TABLES

Table 1.              New Cancer Cases Registered Worldwide, 2020

Table 2.              North America Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

Table 3.              US: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 4.              US: Neoantigens Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)

Table 5.              Canada: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 6.              Canada: Neoantigens Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)

Table 7.              Mexico: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 8.              Mexico: Neoantigens Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)

Table 9.              Market Developments Done By Companies

Table 10.            Glossary of Terms, Neoantigens Market

LIST OF FIGURES

Figure 1.            North America Neoantigens Market Segmentation

Figure 2.            North America Neoantigens Segmentation, By Country

Figure 3.            North America Neoantigens Market Overview

Figure 4.            Combination Therapy Segment Holds Largest Share of North America Neoantigens Market

Figure 5.            US to Show Remarkable Growth During Forecast Period

Figure 6.            North America: PEST Analysis

Figure 7.            Expert Opinion

Figure 8.            North America Neoantigens Market Impact Analysis of Drivers and Restraints

Figure 9.            North America Neoantigens Market – Revenue Forecast and Analysis – 2023- 2028

Figure 10.          North America Neoantigens Market Revenue Share, by Treatment (2023 and 2028)

Figure 11.          Combination Therapy: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 12.          Mono Therapy: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 13.          North America Neoantigens Market Revenue Share, by Therapeutic Specialty (2023 and 2028)

Figure 14.          Gastrointestinal Cancer: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 15.          Lung Cancer: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 16.          Solid Tumors: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 17.          Urinary System Cancers: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 18.          Melanoma: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 19.          Head and Neck Cancers: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 20.          Others: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 21.          North America: Neoantigens Market, by Key Country – Revenue (2023) (USD Thousand)

Figure 22.          North America: Neoantigens Market, by Country, 2023 & 2028 (%)

Figure 23.          US: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 24.          Canada: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 25.          Mexico: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 26.          Impact of COVID-19 Pandemic in North American Country Markets

  1. Advaxis, Inc.
  2. Gradalis, Inc.
  3. Gritstone Oncology
  4. Medigene AG
  5. Moderna, Inc.
  6. Ziopharm Oncology, Inc
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Related Tags North America Neoantigens Market North America Neoantigens Market Research North America Neoantigens Market Insight North America Neoantigens Market Trends North America Neoantigens Market Forecast North America Neoantigens Market Share North America Neoantigens Market 2028 North America Neoantigens Market Growth North America Neoantigens Market Industry Sector North America Neoantigens Market PDF Report North America Neoantigens Market Analysis North America Neoantigens Market Research Competitive Analysis

Purchase Options
Single User License
$3000
Site License
$4000
Enterprise License
$5000